signal recognition particle 72Genealiases: BMFF · BMFS1 · HEL103
Q-omics provides the consensus-scored SRP72 profile across patient tissues and cancer cell-line models. SRP72 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SRP72 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SRP72 protein abundance shows 23,399 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where SRP72 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRP72 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRP72 survival associations across molecular data types. SRP72 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRP72 RNA expression–survival associations across cancer types. High SRP72 expression shows unfavorable associations in CESC, LIHC and KIRP, but favorable associations in KIRC, UCS and READ. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for SRP72 RNA expression.
This table summarizes SRP72 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SRP72. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRP72 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, BLCA and STAD. The HNSC box plot shows higher SRP72 RNA expression in tumor versus normal tissue (log2 FC = +0.657, t-test p < 0.001).
This table shows molecular features associated with SRP72 in patient tissues and cancer cell lines. In patient samples, SRP72 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRP72 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
